Tisdag 4 Augusti | 12:19:17 Europe / Stockholm
Est. tid*
2028-01-28 N/A Bokslutskommuniké 2027
2027-10-25 07:30 Kvartalsrapport 2027-Q3
2027-07-27 07:30 Kvartalsrapport 2027-Q2
2027-04-23 07:30 Kvartalsrapport 2027-Q1
2027-01-29 N/A Bokslutskommuniké 2026
2026-10-30 07:30 Kvartalsrapport 2026-Q3
2026-07-30 - Kvartalsrapport 2026-Q2
2026-05-05 - X-dag ordinarie utdelning SAN 4.12 EUR
2026-04-29 - Årsstämma
2026-04-29 - Extra Bolagsstämma
2026-04-23 - Kvartalsrapport 2026-Q1
2026-01-29 - Bokslutskommuniké 2025
2025-10-24 - Kvartalsrapport 2025-Q3
2025-07-31 - Kvartalsrapport 2025-Q2
2025-05-12 - X-dag ordinarie utdelning SAN 3.92 EUR
2025-04-30 - Extra Bolagsstämma
2025-04-30 - Årsstämma
2025-04-24 - Kvartalsrapport 2025-Q1
2025-01-30 - Bokslutskommuniké 2024
2024-10-25 - Kvartalsrapport 2024-Q3
2024-07-25 - Kvartalsrapport 2024-Q2
2024-05-13 - X-dag ordinarie utdelning SAN 3.76 EUR
2024-04-30 - Extra Bolagsstämma
2024-04-30 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-01 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-28 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning SAN 3.56 EUR
2023-05-25 - Extra Bolagsstämma
2023-05-25 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-03 - Bokslutskommuniké 2022
2022-10-28 - Kvartalsrapport 2022-Q3
2022-07-28 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SAN 3.33 EUR
2022-05-03 - Extra Bolagsstämma
2022-05-03 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-04 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-29 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning SAN 3.20 EUR
2021-04-30 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-05 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-07-29 - Kvartalsrapport 2020-Q2
2020-05-04 - X-dag ordinarie utdelning SAN 3.15 EUR
2020-04-28 - Extra Bolagsstämma
2020-04-28 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-07-29 - Kvartalsrapport 2019-Q2
2019-04-26 - Kvartalsrapport 2019-Q1
LandFrankrike
SektorHälsovård
IndustriLäkemedel & Handel
Sanofi är ett globalt läkemedelsbolag med fokus på forskning, utveckling och marknadsföring av en mängd olika läkemedel, exempelvis för behandling av sjukdomar inom hjärta/kärl/metabolism, multipel skleros, inflammationer och cancer. Bolaget erbjuder även läkemedel för allergier och förkylning. Sanofi grundades 1973 och har sitt huvudkontor i Frankrike.

All ägardata du vill ha finns i Holdings!

Press Release: Sanofi Foundation opens new chapter centered on future generations

2026-06-25 08:00:00

Sanofi Foundation opens new chapter centered on future generations

Paris, June 25, 2026The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases. Through the Foundation, Sanofi extends its commitment to improving people's lives beyond healthcare by supporting younger generations facing some of today's most pressing health, climate, and humanitarian challenges.

"The challenges facing younger generations today extend far beyond access to healthcare alone. By strengthening the focus of the Sanofi Foundation, we are reaffirming our conviction that companies have a role to play in helping create the conditions for every child and young person to thrive, contribute and look to the future with confidence,” said Frédéric OudéaChairman of the Board of Directors Sanofi Foundationand Chairman of the Board of Directors Sanofi

At the heart of this new direction is a simple belief: no child should be defined or limited by a disease. Working alongside NGOs, patient organizations, healthcare professionals, and local communities, the Foundation develops programs that help young people learn, grow, build relationships, and participate fully in society despite the challenges they face.

This ambition is reflected in partnerships such as the one with the Cerebral Palsy Foundation, which will help improve early diagnosis of cerebral palsy in nearly 1,000 children, with the goal of promoting early intervention, better care, and greater long-term independence. It is also demonstrated through the collaboration with AIDA, which will support up to 1,600 young people during and after hospitalization to promote their well-being, inclusion, and confidence in the future.

At the same time, the Foundation continues its longstanding commitment to humanitarian action and strengthening the resilience of vulnerable communities facing climate-related health risks. Since its inception, its humanitarian efforts have reached more than 26 million patients in 45 countries, enabling the distribution of 128 million treatments through 177 humanitarian donations, representing more than 9 million medication packs. As part of its humanitarian commitment, it continues to support the World Health Organization's goal of eliminating sleeping sickness by 2030.

To support this new phase of its development, the Sanofi Foundation is mobilizing an annual budget of €15 million for its programs benefiting children and young people, while continuing its commitments in humanitarian action and climate resilience. Through this strengthened strategy, the Sanofi Foundation aims to have a positive impact on more than 6 million children and young people by 2030.


 

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

  
Media Relations 

Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com

Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com

Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Laura Romby| +33 6 74 16 74 29 | laura.romby@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
 
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com